Company profile
ATEA PHARMACEUTICALS, INC.
NASDAQ:AVIRBiotechnology: Pharmaceutical Preparations
Drug pipeline (1)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| BEMNIFOSBUVIR SULFATE | phase2 | — | 12 | completed, terminated, withdrawn |
Revenue is the latest quarter the company reported for that product, from SEC filings; a fourth quarter is the year less nine months when no filing states one. Trial counts are of the product's ingredients, deduplicated by trial, so products sharing an ingredient share trials.
Clinical trials (33)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT05904470 | phase2 | completed | 2023-05-30 | 2024-12-09 | Atea Pharmaceuticals, Inc. | A Phase 2, Safety and Efficacy of Bemnifosbuvir (BEM) and Ruzasvir (RZR) in Subjects With Chronic HCV |
| NCT04877769 | phase1 | completed | 2021-04-25 | 2021-08-31 | Atea Pharmaceuticals, Inc. | Bronchopulmonary PK of AT-527 (R07496998) |
| NCT06868264 | phase3 | active_not_recruiting | 2025-04-07 | 2026-09-01 | Atea Pharmaceuticals, Inc. | C-BEYOND: Efficacy and Safety of BEM/RZR vs. SOF/VEL in Subjects With Chronic HCV |
| NCT07037277 | phase3 | active_not_recruiting | 2025-06-02 | 2026-12-01 | Atea Pharmaceuticals, Inc. | C-Forward: Efficacy and Safety of BEM/RZR vs SOF/VEL in Subjects With Chronic HCV |
| NCT07314346 | phase1 | recruiting | 2025-01-07 | 2026-08-01 | Atea Pharmaceuticals, Inc. | Drug-drug Interaction Study of Bemnifosbuvir/Ruzasvir (BEM/RZR) and Buprenorphine/Naloxone or Methadone |
FDA applications (0)
No records yet.